Michael Halter
Family Medicine · Tyrone, PANPI 1134199219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 550 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,420 and has fallen 74.2% since, to $624 in 2025. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 550 payments — averaging $13.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$968
- Lilly USA, LLC$837
- Sanofi-aventis U.S. LLC$668
- Novo Nordisk$665
- AstraZeneca$617
- AbbVie$556
- plus $3K from 30 others
What the payments were for
- Speaking & faculty fees$871%
- Food & beverage$7,33998%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 105 | $968 |
| Lilly USA, LLC | 65 | $837 |
| Sanofi-aventis U.S. LLC | 37 | $668 |
| Novo Nordisk | 56 | $665 |
| AstraZeneca | 41 | $617 |
| AbbVie(2 entities) | 29 | $556 |
| Pfizer | 54 | $448 |
| Boehringer Ingelheim | 22 | $292 |
| Amgen | 18 | $283 |
| Merck | 18 | $269 |
| Corcept Therapeutics | 10 | $254 |
| Novartis | 9 | $236 |
| Johnson & Johnson | 13 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $197 |
| Kowa Pharmaceuticals America, Inc. | 8 | $122 |
| Teva Pharmaceuticals USA, Inc. | 7 | $122 |
| Abbott | 4 | $78 |
| Amarin Pharma, Inc. | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Astellas Pharma US Inc | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $53 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Ardelyx, Inc. | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Gilead | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,469 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 24 | $26,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,016 |
| JardianceEmpagliflozin | 18 | $19,152 |
| FarxigaDapagliflozin Propanediol | 24 | $17,353 |
| EliquisApixaban | 20 | $15,535 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $1,725 |
| Atorvastatin Calcium | 61 | $691 |
| Rosuvastatin Calcium | 37 | $606 |
| Levothyroxine Sodium | 27 | $480 |
| Omeprazole | 30 | $419 |
| Metoprolol Succinate | 25 | $371 |
| Gabapentin | 29 | $292 |
| Pantoprazole Sodium | 25 | $290 |
| Ropinirole Hcl | 13 | $275 |
| Potassium Chloride | 12 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $837 | $26,50724 claims |
| GSKTrelegy Ellipta | $968 | $23,01636 claims |
| Boehringer IngelheimJardiance | $292 | $19,15218 claims |
| AstraZenecaFarxiga | $617 | $17,35324 claims |
| PfizerEliquis | $448 | $15,53520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Tyrone
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.